In Vivo Grade Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-31), Mouse IgG2a Kappa PA007515.m2a Syd Labs

Anti-mouse VEGF Monoclonal Antibody (Clone: G6-31) | PA007515.m2a

Name: Anti-mouse VEGF Monoclonal Antibody (Clone: G6-31) | PA007515.m2a
Brand: Syd Labs
SKU: PA007515.m2a
Availability: InStock

Catalog No.: PA007515.m2a | Isotype: Mouse IgG2a Kappa | In Vivo Grade

$200.00 – $1,250.00

Recombinant Mouse IgG2a isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

Details & Specifications
References

Catalog No.	PA007515.m2a
Product Name	In Vivo Grade Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-31), Mouse IgG2a Kappa
Data Sheet	📄 Download Product Data Sheet (PDF)
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Vascular endothelial growth factor; VEGF
Clone	G6-31.
Isotype	Mouse IgG2a Kappa.
Specificity/Sensitivity	The in vivo grade recombinant mouse monoclonal antibody (clone: G6-31) specifically binds to mouse VEGF.
Applications	ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse VEGF protein.
Form Of Antibody	0.2 μM filtered solution of 1x PBS.
Endotoxin	Less than 1 EU/mg of protein as determined by LAL method.
Purity	>95% by SDS-PAGE under reducing conditions.
Shipping	The In Vivo Grade Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-31), Mouse IgG2a Kappa are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Recombinant Mouse IgG2a isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

PA007515.m2a: Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-31), Mouse IgG2a Kappa, In Vivo Grade

The in vivo grade recombinant anti-mouse VEGF mouse IgG2a kappa monoclonal antibody was produced in mammalian cells.

References of Anti-mouse VEGF Monoclonal Antibody (Clone: G6-31)

1. Inhibitory effects of anti-VEGF antibody on the growth and angiogenesis of estrogen-induced pituitary prolactinoma in Fischer 344 Rats: animal model of VEGF-targeted therapy for human endocrine tumors.
Katsuhiro Miyajima, et al.Acta Histochem Cytochem. 2010 May 1;43(2):33-44. PMID: 20514290
“To investigate whether tumor development in E2-induced PRLoma is inhibited by anti-VEGF monoclonal antibody (G6-31), we evaluated tumor growth and observed the vascular structures. With simultaneous treatment with G6-31 for the latter three weeks of the 13-week period of E2 stimulation (E2+G6-31 group), the following inhibitory effects on the PRLoma were observed in the E2+G6-31 group as compared with the E2-only group. In the E2+G6-31 group, a tendency to reduction in pituitary weight was observed and significant differences were observed as (1) reductions in the Ki-67-positive anterior cells, (2) increases in TUNEL-positive anterior cells, and (3) repair of the microvessel count by CD34-immunohistochemistry.”

2. Sprouting Angiogenesis in Human Pituitary Adenomas.
Jie Zhou, et al.Front Oncol. 2022 May 5;12:875219. PMID: 35600354
“Anti-VEGF treatment has been demonstrated to successfully treat pituitary tumors in mouse models. Korsisaari et al. used the anti-VEGF antibody G6-31 to treat pituitary tumors in Men1+/- mice (53). After 67 days, they observed that G6-31 treatment reduced the tumor volume by 72% compared to the control group and significantly extended their survival. All pituitary tumors in Men1+/- mice were later identified as prolactinomas (53). The G6-31 antibody was also used to treat Drd2(-/-) mice with hyperplastic pituitary glands by Luque et al. (54).”

3. Antibodies blocking PlGF or VEGF interactions with the NRP1 receptor mediate anti-proliferative effects.
Samuel A Blackman, et al.bioRxiv. 2025 Oct 26;2025.10.25.684565. PMID: 41306516
“This can occur via multiple mechanisms, including upregulation of placental growth factor 2 (PlGF-2), an alternative ligand for VEGF receptor 1 (VEGFR1) and neuropilin receptor 1 (NRP1). Activity of both growth factors is mediated by interactions with multiple receptors and extra-cellular matrix components, which complicates efforts to understand their contributions to cancer progression. To complement existing antibodies, we discovered those blocking interactions between PlGF-2 or VEGFA and their shared NRP1 receptor in the presence of heparin. Limiting angiogenesis to promote vascular normalization is one mechanism of anti-VEGF protection; here, anti-VEGFA antibodies blocking interactions with VEGFR1 and NRP1 reduced HUVEC tube formation in a physiological angiogenesis model.”

For more technical references or data sheets regarding the Anti-mouse VEGF antibody (Clone: G6-31) formats, please contact our scientific support team at message@sydlabs.com.

Related Recombinant IgG Reference Antibodies:
Recombinant mouse IgG2a isotype control antibody, In vivo grade